FLT3 mutations represent a cornerstone in the pathogenesis and treatment of AML. The integration of NGS into clinical workflows enhances mutation detection, risk stratification, and MRD monitoring.

Some people with acute myeloid leukemia (AML) have a mutation in the FLT3 gene. Targeted therapies called FLT3 inhibitors can help treat AML in people with this mutation.

New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinibREDWOOD CITY, Calif ...

In AML, functional genomics studies have demonstrated a lineage-wide dependency on MYB, consistent with its involvement in disease driven by multiple oncogenic abnormalities (e.g. MLLr, NPM1, FLT3 ...

The exact role of mutant p53 in tumor maintenance is unknown, as studies typically either express mutant p53 in all cells or remove mutant p53 in both tumor cells and the tumor microenvironment.

Oncology/Hematology > Leukemia FLT3 Inhibitor Highly Active in Newly Diagnosed Acute Myeloid Leukemia — Complete response rate of 86%, median event-free survival approaching 4 years with ...

1 Lam, S. and Leung, A. 2020. Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML. International Journal of Molecular Science, 21 (4): 1537. Gebru, M. and Wang, H-G. 2020.

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025 Provided by GlobeNewswire Jun 13, 2025, 3:45:00 AM ...